Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608158 | 0.95 | MAOB (0.43) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL12371708 | 0.95 | PRKCQ (0.42) | HTR6MAOBUSP1ADORA3PRKCQ | |
| SCHEMBL13608345 | 0.92 | KDM1A (0.42) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL13608410 | 0.91 | HTR6 (0.43) | HTR6MAOBKDM1APRKCQPDE9A | |
| SCHEMBL13608434 | 0.91 | KDM1A (0.45) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL13608387 | 0.91 | ADORA3 (0.48) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL13608168 | 0.91 | KDM1A (0.43) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL3845143 | 0.90 | BRD4 (0.40) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL13608417 | 0.90 | KDM1A (0.44) | HTR6MAOBKDM1AUSP1ADORA3 | |
| SCHEMBL13608235 | 0.90 | PRKCQ (0.40) | HTR6MAOBKDM1AUSP1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2008143674-A1 | PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | HTR6 2702/4885MAOB 2855/4885KDM1A 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.